Implementation of Guidelines for Metabolic Syndrome Control in Kidney Transplant Recipients: Results at a Single Center

Overview

Journal Diabetol Metab Syndr

Publisher Biomed Central

Specialty Endocrinology

Date 2015 Oct 20

PMID 26478748

Citations 1

Authors

Inbal Houri

Keren Tzukert

Irit Mor-Yosef Levi

Michal Aharon

Aharon Bloch

Olga Gotsman

Rebecca Backenroth

Ronen Levi

Iddo Ben Dov

Dvora Rubinger

Michal Dranitzki Elhalel

Affiliations

Soon will be listed here.

Abstract

Background: Cardiovascular disease is a leading cause of death among kidney transplant recipients. Metabolic syndrome increases the risk for cardiovascular events and decreases graft survival. Lately, guidelines for management of the metabolic syndrome, primarily hypertension, diabetes mellitus (DM) and hypercholesterolemia have dramatically changed in an attempt to decrease cardiovascular risks among kidney transplant recipients. In the present study we examined whether these guideline changes had impact on our management of post-transplantation patients and the subsequent treatment outcomes for these diseases.

Methods: Data were obtained from kidney transplant clinic files from two follow-up (FU) periods-between 1994-1997 and between 2008-2011. Demographic data, monitoring and screening frequency for cardiovascular risk factors, immunosuppression regimen, treatment for hypertension, diabetes and hyperlipidemia, treatment outcomes and graft function changes were compared between the two follow-up periods.

Results: There was a significant increase in the percentage of patients undergoing transplantation due to renal failure secondary to diabetes and/or hypertension. Patient monitoring and screening during the second FU period were less frequent, but more targeted, reflecting changes in clinic routines. Blood pressure was better controlled in the second FU period (p < 0.01), as was hypercholesterolemia (p < 0.001). High fasting glucose levels were more prevalent among patients in the second group (p < 0.005), although more patients received treatment for DM (p < 0.001). Significantly, fewer patients experienced deterioration of kidney functions during the second FU period (p < 0.001).

Conclusions: We found that guideline changes had impact on clinical practice, which translated to better control of the metabolic syndrome. DM control is challenging. Overall, stability of kidney function improved.

Citing Articles

Ultrasound Assessment of Intima-media Thickness and Diameter of Carotid Arteries in Patients Undergoing Hemodialysis or Renal Transplantation.

Li Z, Du L, Qin Y, Liu J, Luo X Curr Med Sci. 2018; 38(4):727-733.

PMID: 30128885 DOI: 10.1007/s11596-018-1937-7.

References

Fernandez-Fresnedo G, Escallada R, de Francisco A, Rodrigo E, Zubimendi J, Ruiz J . Posttransplant diabetes is a cardiovascular risk factor in renal transplant patients. Transplant Proc. 2003; 35(2):700. DOI: 10.1016/s0041-1345(03)00052-6. View

Ponticelli C, Cucchiari D, Graziani G . Hypertension in kidney transplant recipients. Transpl Int. 2011; 24(6):523-33. DOI: 10.1111/j.1432-2277.2011.01242.x. View

Carpenter M, Weir M, Adey D, House A, Bostom A, Kusek J . Inadequacy of cardiovascular risk factor management in chronic kidney transplantation - evidence from the FAVORIT study. Clin Transplant. 2012; 26(4):E438-46. PMC: 4388027. DOI: 10.1111/j.1399-0012.2012.01676.x. View

Holdaas H, Fellstrom B, Jardine A, Holme I, Nyberg G, Fauchald P . Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003; 361(9374):2024-31. DOI: 10.1016/S0140-6736(03)13638-0. View

. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993; 269(23):3015-23. View

Salerno M, Piselli P, Rossi E, Favi E, Gargiulo A, Spagnoletti G . Metabolic syndrome and cardiovascular disease in kidney transplantation. Transplant Proc. 2011; 43(4):1067-8. DOI: 10.1016/j.transproceed.2011.03.019. View

Alberti K, Zimmet P, Shaw J . Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006; 23(5):469-80. DOI: 10.1111/j.1464-5491.2006.01858.x. View

Rubin M . Hypertension following kidney transplantation. Adv Chronic Kidney Dis. 2011; 18(1):17-22. DOI: 10.1053/j.ackd.2010.10.006. View

Kasiske B, Cosio F, Beto J, Bolton K, Chavers B, Grimm Jr R . Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant. 2004; 4 Suppl 7:13-53. DOI: 10.1111/j.1600-6135.2004.0355.x. View

10.

Courivaud C, Kazory A, Simula-Faivre D, Chalopin J, Ducloux D . Metabolic syndrome and atherosclerotic events in renal transplant recipients. Transplantation. 2007; 83(12):1577-81. DOI: 10.1097/01.tp.0000266898.93894.3d. View

11.

Cosio F, Hickson L, Griffin M, Stegall M, Kudva Y . Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes. Am J Transplant. 2008; 8(3):593-9. DOI: 10.1111/j.1600-6143.2007.02101.x. View

12.

Hernandez D, Muriel A, Abraira V, Perez G, Porrini E, Marrero D . Renin-angiotensin system blockade and kidney transplantation: a longitudinal cohort study. Nephrol Dial Transplant. 2011; 27(1):417-22. DOI: 10.1093/ndt/gfr276. View

13.

Kasiske B, Zeier M, Chapman J, Craig J, Ekberg H, Garvey C . KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int. 2009; 77(4):299-311. DOI: 10.1038/ki.2009.377. View

14.

Hricik D . Metabolic syndrome in kidney transplantation: management of risk factors. Clin J Am Soc Nephrol. 2011; 6(7):1781-5. DOI: 10.2215/CJN.01200211. View

15.

Lentine K, Brennan D, Schnitzler M . Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol. 2004; 16(2):496-506. DOI: 10.1681/ASN.2004070580. View

16.

Porrini E, Delgado P, Bigo C, Alvarez A, Cobo M, Checa M . Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. Am J Kidney Dis. 2006; 48(1):134-42. DOI: 10.1053/j.ajkd.2006.04.078. View

17.

Leslie R . United Kingdom prospective diabetes study (UKPDS): what now or so what?. Diabetes Metab Res Rev. 1999; 15(1):65-71. DOI: 10.1002/(sici)1520-7560(199901/02)15:1<65::aid-dmrr3>3.0.co;2-x. View

18.

Delgado P, Diaz J, Silva I, Osorio J, Osuna A, Bayes B . Unmasking glucose metabolism alterations in stable renal transplant recipients: a multicenter study. Clin J Am Soc Nephrol. 2008; 3(3):808-13. PMC: 2386704. DOI: 10.2215/CJN.04921107. View

19.

Wolfe R, Roys E, Merion R . Trends in organ donation and transplantation in the United States, 1999-2008. Am J Transplant. 2010; 10(4 Pt 2):961-72. DOI: 10.1111/j.1600-6143.2010.03021.x. View

20.

de Vries A, Bakker S, van Son W, Homan van der Heide J, Ploeg R, The H . Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant. 2004; 4(10):1675-83. DOI: 10.1111/j.1600-6143.2004.00558.x. View